Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic Boosts Full-Year 2021 Revenue Guidance by 10 Percent

NEW YORK – SomaLogic on Monday said that it expects to exceed its previous full-year 2021 guidance of $66.7 million in revenues by 10 percent or more.

In a statement, SomaLogic CEO Roy Smythe said that in the first half of 2021 the company "exceeded our expectations with stronger revenue, better gross margins, faster commercial team ramp, and above-plan clinical partnerships."

SomaLogic in March entered into an agreement to merge with CM Life Sciences II, a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital and Corvex Management, with the purpose of listing on the Nasdaq Global Market. The merger is expected to close in the third quarter.